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he anti-angiogenic effect of thrombospondin-1 has
been shown to be mediated through binding of the
type-1 repeat (TSR) domain to the CD36 transmem-
brane receptor. We now report that the TSR domain can
inhibit VEGF-induced migration in human umbilical vein
endothelial cells (HUVEC), cells that lack CD36. More-
over, we identiﬁed 
 
 
 
1
 
 integrins as a critical receptor in
TSR-mediated inhibition of migration in HUVEC. Using
pharmacological inhibitors of downstream VEGF receptor
T
 
effectors, we found that phosphoinositide 3-kinase (PI3k)
was essential for TSR-mediated inhibition of HUVEC mi-
gration, but that neither PLC
 
 
 
 nor Akt was necessary
for this response. Furthermore, 
 
 
 
1
 
 integrins were critical
for TSR-mediated inhibition of microvascular endothelial
cells, cells that express CD36. Together, our results indi-
cate that 
 
 
 
1
 
 integrins mediate the anti-migratory effects of
TSR through a PI3k-dependent mechanism.
 
Introduction
 
Thrombospondin-1 (TSP1) was first identified as a major com-
ponent of platelet 
 
 
 
-granules and as a cell adhesion molecule
found in the matrix (Bornstein, 2001; Lawler, 2002). Since
then, TSP1 has emerged as a complex protein with domain-
specific and cell type–specific effects in cell adhesion, cell sig-
naling, wound healing, and angiogenesis (Adams and Lawler,
2004). TSP1 is a large homotrimeric glycoprotein consisting
of multiple domains that bind to cell surface receptors such
as integrins, the integrin-associated protein (IAP/CD47), or
CD36, and to extracellular molecules including heparin sulfate
proteoglycans and sulfatides (Chen et al., 2000). The binding
sites for these receptors on TSP1 are dispersed throughout the
molecule, with many domains binding multiple receptors.
Soluble TSP1 is a specific inhibitor of angiogenesis and tumor
growth in mice that mediates its effects via modulation of en-
dothelial cell adhesion, proliferation, and motility (Good et al.,
1990; Volpert et al., 1998; Iruela-Arispe et al., 1999). Although
TSP1 can bind to numerous receptors, the primary anti-angiogenic
activity of TSP1 has been localized to the procollagen domain
and type-1 repeat (TSR) sequence (Tolsma et al., 1993b; Vogel
et al., 1993; Iruela-Arispe et al., 1999). The TSR domain has
been studied extensively and the crystal structure described
(Tan et al., 2002).
The three TSRs of TSP1 comprise an 18-kD peptide with
part of its biological activity mapped to the CSVTCG sequence
(Tolsma et al., 1993a; Dawson et al., 1997), which recognizes
CD36 (Asch et al., 1992). CD36 has been shown to be an im-
portant receptor for TSP1 signaling under many experimental
conditions (Jimenez et al., 2000). There have also been several
reports of TSP1 mediating an anti-angiogenic effect through
sequence motifs other than CSVTCG in the TSR domain
(Dawson et al., 1999). The carboxyl terminus, containing the
IAP/CD47-binding sites, and the amino terminus, containing
 
 
 
3
 
 
 
1
 
-binding sites, may also have a role in TSP1’s anti-angiogenic
effects (Kanda et al., 1999; Chandrasekaran et al., 2000). The
multiplicity of domains and receptors has made it difficult to
determine the precise mechanisms by which TSP1 regulates
cellular functions, including its anti-angiogenic effects.
Integrins are required for cell proliferation, survival, and
migration (Howe et al., 1998; Hynes et al., 2002), and are impor-
tant to the growth of new blood vessels because endothelial cells
proliferate in an anchorage-dependent manner (Ingber, 1990;
Meredith et al., 1993). Integrin antagonists that prevent binding
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of 
 
 
 
v
 
 
 
3
 
 (Brooks et al., 1994), 
 
 
 
v
 
 
 
5
 
 (Friedlander et al., 1995;
Kumar and Li, 2001), and 
 
 
 
5
 
 
 
1
 
 (Kim et al., 2000) to ECMs
suppress tumor growth via angiogenesis inhibition. Interestingly,
certain endogenous angiogenesis inhibitors such as endostatin
(Wickstrom et al., 2002; Sudhakar et al., 2003) and tumstatin
(Maeshima et al., 2001; Wickstrom et al., 2002; Sudhakar et al.,
2003) have been shown to bind directly to integrins.
Migration and reorganization of endothelial cells is in-
duced both in vivo and in vitro by members of the VEGF-plate-
let–derived growth factor supergene family and to a lesser ex-
tent by FGF growth factor families (Nguyen et al., 1994;
Ribatti et al., 2000; Ferrara, 2004). Overexpression of VEGF
by tumor cells has been associated with tumor growth, metasta-
sis, and greater risks of tumor recurrence (Ferrara, 2004). Inhi-
bition of VEGF secretion as well as the inhibition of endothe-
lial cell migration and proliferation increases the apoptotic rate
of tumor cells and blocks capillary sprout formation (Bjorndahl
et al., 2004). In addition, several reports indicate that growth
factor signaling pathways can be regulated by integrin clus-
tering and occupation (Ingber, 1990; Miyamoto et al., 1996;
Tsou and Isik, 2001), suggesting crosstalk between integrin
and growth factor signaling pathways.
In the tumor microenvironment, TSP1 is a potent angio-
genesis inhibitor, and the loss of TSP1 expression by tumor
cells contributes to the angiogenic phenotype. Endothelial cell
migration is a critical component of angiogenesis (Zetter,
1980), and inhibition of endothelial migration contributes to
TSP1 suppression of angiogenesis. A better understanding of
the mechanism of TSP1 inhibition of endothelial cell migration
could provide insight for therapeutic strategies. The purpose of
the current study was to investigate the mechanism through
which the TSR domain inhibits cell migration induced by
VEGF. We used human umbilical vein endothelial cells (HU-
VEC), cells that lack the CD36 receptor, along with human mi-
crovascular endothelial cells (HMVEC) that express CD36, to
investigate this mechanism. Our results are consistent with a
role for 
 
 
 
1
 
 integrins as mediators of TSR inhibition of endothe-
lial cell migration.
 
Results
 
TSR inhibits VEGF-induced HUVEC 
migration
 
It has been reported that the TSRs mediate an anti-angiogenic
effect through the CD36 receptor on endothelial cells (Jimenez
et al., 2000). Here, we show that TSR inhibited VEGF-induced
HUVEC migration in a dose-responsive manner (Fig. 1 A). In
fact, TSR inhibited migration as efficiently as TSP1 (Fig. 1 A).
The inhibitory effect of TSP1 and TSR on cell migration was
not the result of decreased adhesion, as assessed by measuring
cell attachment to fibronectin in the presence or absence of
TSP1 or TSR (Fig. 1 B).
Although it has been reported that HUVEC do not ex-
press the CD36 receptor (Swerlick et al., 1992), we considered
the possibility that the HUVEC used in this study might ex-
press CD36. In the presence of a known blocking antibody
against CD36, TSR was still able to inhibit VEGF-induced mi-
gration in HUVEC (Fig. 1 C). FACS analysis also confirmed
the absence of CD36 in HUVEC compared with HMVEC,
which express significant levels of this protein (unpublished
data). These findings demonstrate that TSR can repress VEGF-
stimulated HUVEC migration and suggests that this effect is
mediated in the absence of CD36.
 
TSR inhibits HUVEC migration through 
 
 
 
1
 
 integrins
 
Because TSP1 binds to 
 
 
 
1
 
 and 
 
 
 
3
 
 integrins via various domains
across TSP1, we considered the possibility of TSR associating
with 
 
 
 
 integrins in HUVEC. FACS analysis showed abundant
levels of 
 
 
 
1
 
 on these cells (Table I). Antibodies against 
 
 
 
1
 
 and
 
 
 
3
 
 integrin subunits were used to examine the role of these re-
ceptors in TSR inhibition of VEGF-induced migration. A 
 
 
 
1
 
 in-
tegrin antibody (clone PC410) was able to inhibit cell migra-
tion in a dose-dependent manner (Fig. 2 A). The PC410 
 
 
 
1
 
antibody is also able to activate the 
 
 
 
1
 
 integrin signaling path-
way (Miller et al., 1999). When used at 2 
 
 
 
g/ml, a concentra-
tion that has only a slight effect on VEGF-induced migration,
Figure 1. TSP1 and TSR inhibit VEGF-induced HUVEC migration. (A) A
modified Boyden chamber assay was used to characterize VEGF-induced
(3–5 ng/ml) migration of HUVEC. Cell migration is expressed as percent-
age of the maximal migration induced by VEGF. Dashed lines indicate
basal migration levels, in the absence of VEGF. TSP1 and TSR concentra-
tions are presented as both nM and  g/ml. Where indicated, suspended
cells were treated with TSP1 (solid bars) or TSR (open bars) for 30 min,
placed in migration chambers, and allowed to migrate to VEGF for 4 h.
(B) The effect of cell adhesion in TSP1/TSR-treated cells was measured.
HUVEC were pretreated with either TSP1 (solid bars) or TSR (open bars)
for 30 min before plating on fibronectin-coated wells for 1.5 h. Adhesion
was determined by measuring the absorbance at 590 nm of crystal violet–
stained cells. (C) HUVEC were treated with an antibody against CD36
(5  g/ml) for 10 min, followed by the addition of TSR (16 nM) for 30 min
and were allowed to migrate to VEGF for 4 h. Error bars indicate SDs.
*, P   0.05, **, P   0.01 compared with VEGF alone as determined
using t test for unpaired data. 
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the PC410 antibody was able to prevent the inhibition of mi-
gration mediated by TSR (Fig. 2 B). On the contrary, a nonacti-
vating 
 
 
 
1
 
 antibody (MAB2000) had no protective effect (Fig.
2 B). Similarly, a 
 
 
 
3
 
 integrin antibody could not rescue TSR-
inhibited migration (Fig. 2 C). Collectively, these data suggest
that the inhibitory effect of TSR on cell migration is overcome
by the activation of 
 
 
 
1
 
 integrins.
 
 
 
 integrin small interfering RNA (siRNA) was used to
confirm the role of 
 
 
 
1
 
 integrins in the TSR-inhibited migration.
Fig. 2 D shows that 
 
 
 
1
 
 and 
 
 
 
3
 
 integrin levels were significantly
reduced in cells transfected with 
 
 
 
1
 
- or 
 
 
 
3
 
-siRNA compared
with cells transfected with a control siRNA. Silencing of 
 
 
 
1
 
 or
 
 
 
3
 
 integrins did not prevent VEGF-induced cell migration (Fig.
2 E, solid and striped bars, respectively). We hypothesized that
in HUVEC, 
 
 
 
3
 
 integrins mediated adhesion and migration when
 
 
 
1
 
 levels were reduced by siRNA. It has previously been shown
that overexpression of nonfunctional 
 
 
 
1
 
 integrin stabilized 
 
 
 
3
 
integrin mRNA (Retta et al., 2001). Moreover, in microvascular
endothelial cells (Cheng et al., 1991) and smooth muscle cells
(Clyman et al., 1992), 
 
 
 
3
 
 integrins were shown to mediate cell
adhesion and migration on fibronectin. In cells with reduced 
 
 
 
1
 
levels, TSR was ineffective in inhibiting VEGF-induced migra-
tion (Fig. 2 E, solid bars). In contrast, reducing the level of 
 
 
 
3
 
Table I. 
 
Alpha integrin subunit expression in HUVEC
Integrin subunit % maximal mean expression
 
 
 
1
 
1.000
 
 
 
1
 
0.014
 
 
 
2
 
1.050
 
 
 
3
 
0.870
 
 
 
4
 
0.003
 
 
 
5
 
0.930
 
 
 
6
 
0.620
 
 
 
v
 
0.980
 
Cells (0.5 
 
 
 
 10
 
6
 
) were incubated with primary antibodies, washed, incubated
with IgG conjugated to R-phycoerythrin, fixed, and analyzed for fluorescence
using flow cytometry. Relative fluorescence intensity is expressed as a percentage
of 
 
 
 
1
 
 fluorescence.
Figure 2. TSR inhibits migration through  1 integrins.
(A) Cells were treated with increasing concentrations of
an antibody (clone PC410) against  1 and were allowed
to migrate to VEGF for 4 h. (B) Cells were treated with
antibodies against  1 (2  g/ml) followed by addition of
TSR (16 nM) before migration to VEGF for 4 h. Treatment
with the PC410  1 antibody prevented TSR from inhibiting
migration, whereas MAB2000  1 antibody had no effect.
(C) Treatment with the  3 antibody had no effect on TSR-
mediated inhibition of migration. Cells were treated with
an antibody against  3 (2  g/ml) followed by addition of
TSR (16 nM) before migration to VEGF for 4 h. (D) HUVEC
were transfected with either control siRNA (C-siRNA) or
 1-or  3-siRNA. 72 h after transfection, cells were lysed
and integrin  1 and  3 levels were analyzed by Western
blotting. Membranes were stripped and probed for actin
to show equal protein loading. (E) siRNA-transfected cells
were used in the migration assay 72 h after transfection.
Where indicated, control siRNA cells were treated with
the PC410  1-activating antibody followed by treatment
with TSR (16 nM) for 30 min and were then allowed to
migrate to VEGF for 4 h. (F) Ligand-coated Spherotech
beads were incubated with suspended HUVEC, beads
were isolated, and protein resolved by SDS-PAGE. Beads
coated with TSR and RGD (but not HSA) show specific
binding to  1 integrins. *, P   0.05, **, P   0.01
compared with relevant control (VEGF alone or antibody
alone, respectively) as determined using a t test for un-
paired data.JCB • VOLUME 168 • NUMBER 4 • 2005 646
had no effect on TSR’s ability to inhibit cell migration (Fig. 2 E,
striped bars). In cells that were transfected with control siRNA,
TSR was able to inhibit VEGF-induced migration, and this inhi-
bition was diminished by the presence of PC410 (Fig. 2 E, open
bars). Together, these results indicate that inhibition of VEGF-
induced HUVEC migration by TSR is strictly dependent on
levels of  1 integrin expression and activation.
TSR complexes with  1 integrins
Next, we examined whether there was a direct interaction be-
tween TSR and  1 integrins in HUVEC using protein-coated
beads. Beads coated with TSR, an adhesion tripeptide Arg-
Gly-Asp (RGD), or horse serum albumin (HSA) were incu-
bated with suspended HUVEC and bead fractions were sepa-
rated on SDS-PAGE and analyzed by Western blotting. The
immature ( 105 kD) and the mature ( 125 kD) forms (Sali-
cioni et al., 2004) of  1 integrins were detected in fractions pre-
pared from beads coated with either RGD or TSR peptides
(Fig. 2 F), but not from beads coated with HSA, indicating that
TSR has the ability to bind  1 integrins with the same effi-
ciency as RGD peptide, the canonical RGD  1 ligand.
TSR functions through  1 integrins
Next, we sought to identify the   subunit that  1 partners
with for TSR-mediated inhibition of VEGF-induced migration.
FACS analysis showed the expression levels of various   sub-
units in HUVEC (Table I). Abundant levels of  2,  3,  5, and
 v, lower levels of  6, and minimal levels of  1 were detected.
Although a recent report shows  4 expressed in HUVEC
(Calzada et al., 2004b), barely detectable levels of  4 were ob-
served here. Several antibodies against   subunits were exam-
ined in the migration assay. Blocking either  3 or  5 prevented
TSR from inhibiting VEGF-induced cell migration, whereas
antibodies to the  2 and  v subunits had no significant effect
(Fig. 3 A).
To examine this in further detail, suspended HUVEC
were incubated with protein-coated beads, and bead fractions
were prepared and analyzed by Western blotting. Both  5 and
 1 integrins were detected in fractions prepared from beads
coated with either RGD or TSR peptides as well as beads
coated with specific  1 integrin antibodies, whereas barely de-
tectable levels were present in fractions prepared from beads
coated with HSA (Fig. 3 B, top).  1 integrins were detected in
Figure 3. TSR complexes with and functions through
 5 1 integrins. (A) Cells were treated with   subunit anti-
bodies (2  g/ml) for 15 min, treated with TSR (16 nM)
for 30 min, and allowed to migrate toward VEGF for 4 h.
(B) Spherotech magnetic substrate-coated beads were
used to prepare supramolecular complexes from sus-
pended HUVEC. Western blotting (WB) analysis using an
 5 1 integrin antibody shows major bands in fractions
prepared from beads coated with TSR, RGD, and  1
antibodies BD15 and MAB2000 ( 1), but not for HSA
(top). The blot was stripped and probed for  1 (bottom).
(C) Spherotech magnetic substrate-coated beads were
used to prepare supramolecular complexes from HUVEC
lysate using 1% NP-40 lysis buffer. Membranes were
probed with an  5 1 antibody. (D) Fibronectin-adherent
HUVEC treated with Spherotech magnetic substrate-
coated beads were immunostained for  5 1 (bottom). Ar-
rows show a representative bead by phase contrast (top).
The arrowhead denotes a cell margin (top). (E) Quanti-
fication of the percent positive beads presented in D.
*, P   0.05, **, P   0.01 compared with VEGF alone
as determined using t test for unpaired data.TSR INHIBITS CELL MIGRATION VIA  1 INTEGRINS • SHORT ET AL. 647
peptide- and antibody-coated beads, but not with HSA-coated
beads (Fig. 3 B, bottom). Interestingly,  5 1 integrins were the
only dimers detected when  1 antibody-coated beads were
used with biotinylated HUVEC (Fig. S1, available at http://
www.jcb.org/cgi/content/full/jcb.200407060/DC1), indicating
that in our experimental conditions,  5 1 integrins were the
predominant  1 dimers expressed.
To determine whether  5 or  1 integrins were the pref-
erential receptor for TSR, immunoprecipitation experiments
were performed with HUVEC lysate. Fig. 3 C shows that only
the  5 subunit was detected in RGD and TSR peptide-coated
bead immunoprecipitates, whereas BD15 antibody-coated
beads specifically recognize  1 integrins. As expected, the
 5 1-coated beads recognize both  5 and  1. No specific signal
was detected with  3 integrin antibody-coated beads, even
when the membrane was stripped and reprobed with an  3-
specific antibody (unpublished results). These data suggest
that in native conditions, both  5 and  1 integrins are potential
receptors for TSR.
We also examined whether TSR-coated beads were able
to bind and cluster with  5 1 integrins in HUVEC. Adherent
cells were incubated with beads coated with HSA, BD15,
TSR, or RGD and immunostained for  5 1. Beads coated with
TSR showed a distinct staining for  5 1 (Fig. 3 D, bottom).
Beads adherent to HUVEC are evident by phase contrast (Fig.
3 D, top). Quantification of these results using computerized
image analysis confirmed that  75% of the beads coated
with RGD, TSR, or BD15 displayed  5 1 integrin staining,
whereas  15% of the HSA-beads were positive (Fig. 3 E).
Together, our results suggest that TSR inhibition of HUVEC
migration is mediated by binding to the  5 1 integrin, a major
fibronectin receptor in HUVEC.
TSR inhibition of VEGF-induced 
migration depends on PI3k
Phosphoinositide 3-kinase (PI3k) and PLC  were examined as
potential downstream targets of TSR function in VEGF-induced
HUVEC migration. As expected, treatment of cells with a
PLC  inhibitor, U73122, resulted in a dose-responsive inhibi-
tion of migration (Fig. 4 A). In the presence of TSR, addition of
U73122 appeared to have an additive effect on inhibiting migra-
tion (Fig. 4 B). Because PLC  inhibition did not interfere with
the inhibitory effects of TSR, it is unlikely that PLC  function
is a rate-determining component of TSR-mediated inhibition.
In the presence of the PI3k inhibitor, LY294002, there
was a dose-responsive inhibition of cell migration (Fig. 4 C).
Similar results were shown using wortmannin (unpublished
data). Addition of TSR did not further reduce migration in the
presence of LY294002 (Fig. 4 D), suggesting PI3k as a candi-
date for mediation of TSR effects.
PI3k functions through  1 integrins in 
VEGF-induced migration
Considering our results indicating that TSRs inhibitory effects
on migration depend on PI3k and  1, we next examined
whether   1 integrins mediate TSR’s inhibitory effects via
PI3k. Inhibition of cell migration induced by treatment with
LY294002 was blocked by preincubation of cells with PC410,
whereas MAB2000 had no protective effect (Fig. 5 A). These
results suggest that the role of PI3k on cell migration is at least
in part dependent on the level of activation of  1 integrins at
the time TSR was added. Interestingly, we found that the p85
subunit of PI3k coimmunoprecipitated with  1 integrins (Fig. 5 B),
indicating that a pool of PI3k was directly associated with  1
integrins in HUVEC. Using  1 siRNA, we next examined
whether the PI3k associated with  1 integrins was responsi-
ble  for LY294002 mediated inhibition of cell migration. In
cells with diminished levels of  1 integrins, pretreatment with
LY294002 alone or in association with TSR was not able to in-
hibit VEGF-induced migration (Fig. 5 C, solid bars) compared
with control siRNA-treated cells (Fig. 5 C, open bars). Con-
versely, overexpression of the myristoylated p110 subunit of
PI3k, a constitutively active form of PI3k associated with the
cell membrane, prevented both LY294002 and TSR from in-
hibiting migration (Fig. 5 D, solid bars). The functionality of
the overexpressed p110 was confirmed by increased Akt phos-
phorylation levels in the transfected cells (Fig. 5 D, inset).
These data further support the hypothesis that TSR inhibits
HUVEC migration via regulation of the PI3k activity associ-
ated with  1 integrins.
Contrary to what was observed with the PI3k inhibi-
tor, inhibition of VEGF-induced cell migration using U73122
could not be rescued using PC410, indicating that although
Figure 4. TSR inhibition of migration is dependent on PI3k, but independent
of PLC . (A) HUVEC were treated with the indicated concentrations of the
PLC  inhibitor U73122 and were allowed to migrate to VEGF (5 ng/ml)
for 4 h. (B) HUVEC were treated with U73122 (2  M) for 10 min fol-
lowed by treatment with TSR (16 nM) for 30 min and allowed to migrate
to VEGF for 4 h. (C) Cells were pretreated with increasing amounts of a
PI3k inhibitor, LY294002, and allowed to migrate to VEGF (5 ng/ml) for
4 h. (D) Cells were treated with LY294002 (5  M) for 10 min followed by
treatment with TSR (16 nM) for 30 min, and allowed to migrate to VEGF
for 4 h. *, P   0.05, **, P   0.01 compared with VEGF alone as deter-
mined using t test for unpaired data.JCB • VOLUME 168 • NUMBER 4 • 2005 648
PLC  functions downstream from the VEGF receptor in mi-
gration, it does not require  1 integrins for activity (Fig. 5 A).
Active Akt is not required for VEGF-
induced migration
Because Akt is a downstream target of PI3k, we examined
whether it is part of the TSR- 1-PI3k pathway. TSR had no ef-
fect on VEGF-induced Akt phosphorylation, whereas treatment
with LY294002 inhibited VEGF-induced Akt phosphorylation
(Fig. 6 A, top). Furthermore, TSR caused no additional de-
crease in Akt phosphorylation in combination with LY294002.
MAPK phosphorylation was then examined by reprobing the
blot. As expected, neither TSR nor LY294002 treatments had
any effect on MAPK phosphorylation induced by VEGF (Fig.
6 A, bottom). We also examined the effect of down-regulation
of Akt expression by siRNA on cell migration. The dramatic
decrease of Akt protein levels (Fig. 6 B, inset) had no signifi-
cant effect on VEGF-induced migration. Interestingly, treat-
ment with TSR and LY294002 was able to significantly inhibit
migration in both control siRNA cells and Akt-siRNA cells
(Fig. 6 B). These results suggest that although PI3k is neces-
sary for VEGF-induced migration, activation of its downstream
effector, Akt, is not required.
TSR inhibits migration through  1 
integrins in cells expressing CD36
Thus far, our data show a dependence on  1 integrins for TSR’s
inhibitory effect on HUVEC migration, cells that lack CD36.
We also examined the role of  1 integrins in HMVEC, cells
that endogenously express CD36. In the presence of a CD36
antibody, we show that TSR is no longer able to inhibit VEGF-
induced HMVEC migration, as anticipated (Fig. 7 A). Surpris-
ingly, however, in the presence of this antibody, the full length
TSP1 could still inhibit VEGF-induced migration (Fig. 7 A).
These data suggest the presence of an additional receptor medi-
ating the anti-migratory effects. Interestingly, addition of the
PC410 antibody was sufficient to prevent both TSP1 and TSR
from inhibiting VEGF-induced migration (Fig. 7 B). Similar to
HUVEC, an antibody against the  3 subunit had no effect on
either TSP1 or TSR inhibition of HMVEC migration (Fig. 7 B).
Figure 5. TSR requires PI3k and  1 integrin for inhibiting
migration. (A) Where indicated, cells were treated with
antibodies against  1 (PC410 or MAB2000; 2  g/ml)
for 10 min, followed by treatment with either LY294002
(5  M) or U73122 (2 nM) for 15 min and were allowed
to migrate to VEGF for 4 h. (B) The p85 subunit of PI3k
coimmunoprecipitates with  1 integrins. Near-confluent
HUVEC were lysed and 200  g of protein was immuno-
precipitated with either anti- 1 antibody (MAB2000) or a
mouse IgG control antibody. Immunocomplexes were
separated by SDS-PAGE and transferred to nitrocellulose.
The membrane was probed with an mAb against the p85
subunit of PI3k, stripped, and reprobed with an mAb
against  1. (C) TSR requires  1 integrins and PI3k to in-
hibit migration. Cells were transfected with either control-
or  1-siRNA. Cells were treated with LY294002 (5  M)
for 10 min, then treated with TSR (16 nM) for 30 min and
allowed to migrate to VEGF for 4 h. (D) Cells were infected
with pLNCX retrovirus, either empty (vec) or containing
myristoylated p110 (m110). Cells were split 24 h after
infection, and 48 h later subjected to a migration assay
or lysed for Western analysis. For the migration assay,
cells were treated with either LY294002 (10  M) or TSR
(16 nM) and allowed to migrate to VEGF for 4 h. *, P  
0.05, **, P   0.01 compared with relevant control
(VEGF alone or antibody alone, respectively) as deter-
mined using a t test for unpaired data.TSR INHIBITS CELL MIGRATION VIA  1 INTEGRINS • SHORT ET AL. 649
These data support a potentially important role for  1 integrins
in facilitating the anti-migratory effect of TSP1 on endothelial
cells, even when CD36 is expressed.
Discussion
Soluble TSP1 inhibits angiogenesis by interacting directly with
endothelial cells. Several recent studies indicate that down-reg-
ulation of TSP1 may have a critical role in the switch to an an-
giogenic phenotype (Campbell et al., 1998; Laderoute et al.,
2000; Doll et al., 2001; Watnick et al., 2003). It is well docu-
mented that endothelial cell migration and proliferation are crit-
ical components of angiogenesis (Folkman, 1995), yet neither
the mechanism of VEGF-mediated endothelial cell migration
nor the inhibitory effects of TSP1 are fully understood. Several
studies have reported that the anti-angiogenic effects of TSP1
are mediated at least in part by CD36, which triggers a signaling
cascade leading to endothelial cell apoptosis and collapse of
tumor vessels (Dawson et al., 1997; Jimenez et al., 2000).
Our study has focused on exploring the mechanism by
which the TSR domain of TSP1 inhibits VEGF-induced migra-
tion of HUVEC. VEGF was used as the chemoattractant to in-
duce migration, as we have previously shown VEGF to be a
more potent chemotactic factor for HUVEC migration than
bFGF (Yoshida et al., 1996). In fact, VEGF has recently been
shown to be the principal effector of the angiogenesis pathway
in endothelial cells, whereas FGF acts primarily by increasing
VEGF expression (Ferrara, 2004). Consistent with a recent re-
port (Calzada et al., 2004b), we find that TSP1 inhibits VEGF-
mediated HUVEC migration. Therefore, we investigated whether
TSR, the previously identified anti-angiogenic domain of
TSP1, mediated inhibition of HUVEC migration. We found
that TSR inhibits VEGF-induced HUVEC migration via a
CD36-independent pathway.
Figure 6. TSR does not require Akt to inhibit migration. (A) Where indi-
cated, near-confluent and serum-starved HUVEC were treated with
LY294002 (5  M) for 10 min, followed by treatment with TSR (16 nM) for
2 h and then with VEGF (5 ng/ml) for 5 min before cell lysis. Lysates were
separated by SDS-PAGE and transferred to nitrocellulose. Membranes
were probed for either phospho-ser473Akt or phospho-MAPK, stripped,
and probed for total Akt or MAPK. (B) Cells were transfected with Akt
siRNA as described in Materials and methods. Where indicated, cells
were treated with LY294002 (5  M) for 10 min, then treated with TSR
(16 nM) for 30 min and allowed to migrate to VEGF (5 ng/ml) for 4 h.
The inset is a Western blot showing Akt-siRNA treatment greatly reduces
total Akt protein levels. *, P   0.05; **, P   0.01 compared with VEGF
alone as determined using a t test for unpaired data.
Figure 7. TSP1 and TSR inhibit migration through  1 integrins in cells
expressing CD36. (A) HMVEC-d were treated with a blocking antibody
against CD36 (5  g/ml) for 10 min, followed by the addition of either
TSP1 (7 nM) or TSR (5 nM) for 30 min. Cells were then placed in Transwell
chambers and allowed to migrate to VEGF for 4 h. (B) HMVEC-d were
treated with antibodies (2  g/ml) against either  1 (PC410) or  3 integrins
for 10 min followed by the addition of either TSP1 (7 nM) or TSR (5 nM)
for 30 min. Cells were allowed to migrate to VEGF (5 ng/ml) for 4 h.
Error bars indicate SDs. *, P   0.05, **, P   0.01 compared with rele-
vant control (VEGF alone or antibody alone, respectively) as determined
using a t test for unpaired data.JCB • VOLUME 168 • NUMBER 4 • 2005 650
TSP1 recognizes multiple receptors, several of which are
integrins. In particular, various domains of TSP1 can bind   in-
tegrins. Furthermore, several reports indicate that growth factor
signaling pathways can be regulated by integrin clustering and
occupation (Ingber, 1990; Miyamoto et al., 1996; Tsou and
Isik, 2001), suggesting crosstalk between integrin and growth
factor signaling pathways (Zachary and Gliki, 2001). We hy-
pothesized that TSR may function through  1 integrins as an
alternative pathway to CD36. We found, by using either a  1-
activating antibody or by suppressing  1 integrins, that TSR
was unable to inhibit VEGF-induced migration, indicating that
 1 is necessary for TSR inhibition of VEGF-induced migration.
We also found a direct interaction of TSR with  1 integrins
by coimmunoprecipitation and colocalization. Because TSR
does not contain an RGD sequence, a sequence present in several
ECM proteins that is recognized by integrins, our data further
indicate that TSR binds  1 through an RGD-independent se-
quence. This is consistent with a recent report showing involve-
ment of  1 in TSR inhibition of cell adhesion (Calzada et al.,
2004a). Endostatin, for example, has been shown to bind to  5 1
(Wickstrom et al., 2002; Sudhakar et al., 2003) through a non-
RGD sequence that promotes endothelial cell adhesion (Wick-
strom et al., 2004). Our data indicate that TSR also binds through
 5 1.  5 integrins were highly expressed in our cells, and block-
ing antibodies to  5 subunits were able to suppress TSR inhibi-
tion of cell migration. We found that  5 1 binds directly to TSR,
and is the most likely target for TSR binding. However,  3 sub-
units were also highly expressed in our cells, and blocking anti-
bodies to  3 were able to suppress the TSR inhibition of cell mi-
gration, despite the lack of any direct evidence for binding of
TSR to  3. A potential alternate explanation could be activation
of the  3 1 integrins downstream of TSR binding to  5 1.
We also investigated the role of downstream signaling
molecules as effectors of TSR binding to  1 integrins. Thus, we
examined two signaling proteins, PLC  and PI3k, that have
been shown to be downstream of VEGF-induced migration in
endothelial cells (Shuster and Herman, 1998; Qi and Claesson-
Welsh, 2001). Consistent with earlier reports (Zeng et al., 2001),
we found that inhibition of PLC  activation was able to block
VEGF-mediated HUVEC migration. Because simultaneous pre-
treatment of HUVEC with TSR plus a PLC  inhibitor had an
additive effect on inhibiting migration, we concluded that PLC 
is not a rate-limiting effector of the TSR-signaling pathway.
There are numerous reports of  1 integrins functioning
through PI3k in other cell types (Berrier et al., 2000; Reyes-
Reyes et al., 2001; Woods et al., 2001; Armulik et al., 2004).
Our results indicate that PI3k is critical for the  1-dependent in-
hibition of HUVEC migration by TSR. These data are consis-
tent with a published report (Dimmeler et al., 2000) showing
that inhibition of PI3k alone was sufficient to reduce VEGF-
induced cell migration. Treatment with TSR was able to inhibit
cell migration as efficiently as the PI3k inhibitors. Simulta-
neous treatment with TSR and LY294002 had no additive effect
beyond that of either LY294002 or TSR alone, implying that
these two agents operate via a common pathway. We also
found that PI3k complexes with  1 integrins. In addition, the
PI3k inhibitor LY294002 did not inhibit migration in the presence
of the  1-activating antibody or in cells where  1 integrin levels
were decreased. These results indicate that inhibition of the
pool of PI3k available to associate with  1 integrins is suffi-
cient to inhibit VEGF-induced migration. In support of this hy-
pothesis, a recent report showed that blockage of  5 integrins in
colon cancer was able to decrease PI3k activation leading to in-
hibition of cell attachment and induction of apoptosis (Murillo
et al., 2004). Another study has identified the membrane-proxi-
mal segment domain of  1 integrins as an important regulator
of PI3k-dependent signaling (Armulik et al., 2004).
Akt is a downstream target of PI3k for VEGF-induced pro-
liferation (Gerber et al., 1998; Thakker et al., 1999). Moreover, a
recent report showed that migration is increased by activating
Akt (Dimmeler et al., 2000). Here, we found that active Akt is
not required for VEGF-induced migration, as migration was not
decreased when Akt levels were silenced. Furthermore, decreas-
ing Akt expression had no effect on TSR inhibition of migration.
Altogether, our data raise the possibility that  1 integrins can reg-
ulate cell migration via a PI3k-dependent, Akt-independent path-
way. This is not entirely unexpected because the time frame of
these effects is not consistent with the cell survival role of Akt.
Together, our data support a pathway for VEGF-medi-
ated HUVEC migration that requires activation of both  1 inte-
grins and PI3k, as VEGF-stimulated HUVEC migration is
blocked by either  1 silencing or by inhibition of PI3k activity.
TSR binds to  5 1 integrins outside of their RGD-binding site.
We propose that this binding allows adhesion of the het-
erodimer to the ECM but prevents integrin conformational
changes proximal to the membrane, which then blocks the acti-
vation of PI3k and results in the inhibition of cell migration. In
the absence of  1, the residual HUVEC migration is probably
mediated via  3 integrins. Under these conditions, TSR no
longer inhibits migration because it does not bind  3. This al-
ternate pathway for VEGF-mediated migration does not pro-
ceed via PI3k because the PI3k inhibitor was unable to block
migration in the absence of  1 integrins.
Our study describes a novel pathway for TSR inhibition
of VEGF-induced endothelial migration through  1 integrins.
We also report that  1 integrins contribute to TSR’s inhibitory
effect on migration in HMVEC, cells that endogenously ex-
press CD36. In HMVEC, a cell type that expresses both CD36
and  1 integrins, each receptor may differentially contribute to
TSP1-mediated migration inhibition depending upon microen-
vironmental cues and on the nature of the migration stimulus.
Because fragments of TSP1 and analogs of TSP1 domains are
currently being tested in the clinical setting as anti-cancer
drugs, it will become increasingly important to understand the
nature of the receptors by which TSP1-derived reagents exert
their anti-endothelial cell effects.
Materials and methods
Materials
mAbs (from CHEMICON International) against integrin subunits included:
activating anti- 1 (clone P4C10), used for FACS and migration assays; a
nonactivating anti- 1, MAB2000, used in migration assays and immuno-
precipitation; anti- 1 (clone B3B11), used for immunoblotting; anti- 3
(clone 25E11) used in migration assays; the   integrin partners kit for  TSR INHIBITS CELL MIGRATION VIA  1 INTEGRINS • SHORT ET AL. 651
subunits; and  5 1 (AB1950) for immunoblotting.  1 mAbs K20 (Beckman
Coulter) and BD15 (Biosource) were used to coat beads, and  1 monoclo-
nal clone W1B10 (Sigma-Aldrich) was used to detect  1 from bead su-
pramolecular complexes.  3 mAb (Biosource International) was used for
immunoblotting. pAbs recognizing MAPK (C-16), His (G-18), and  -actin
were purchased from Santa Cruz Biotechnology, Inc. Phosphorylated Akt
(ser473) antibody was from Cell Signaling and antibody against total Akt
was from Upstate Biotechnology. Anti-active MAPK was from Promega.
The antibody to CD36 was from NeoMarker (Clone 185-1G2). The anti-
p85 mAb was from BD Biosciences. Recombinant VEGF was provided by
Genentech, Inc. Fibronectin was from BD Biosciences. All other reagents
and chemicals were from Sigma-Aldrich unless otherwise indicated.
Proteins
TSP1 and the thrombospondin peptide, TSR, were isolated or prepared as
described previously (Miao et al., 2001). The TSR peptide contained all
three TSRs.
Cell culture
Primary HUVEC and dermal HMVEC (Cambrex/Biowhittaker) were main-
tained according to the supplier’s directions. For experiments, cells were
grown to subconfluence and used between passages 3–7 for HUVEC and
passages 4–8 for HMVEC.
Adhesion assay
96-well plates (Falcon) coated with 10  g/ml fibronectin were washed
with PBS and blocked with endothelial basal medium (EBM) containing 2%
BSA. Where indicated, cells were pretreated with TSP1 or TSR for 30 min.
4   10
4 cells/well in EBM/2% BSA were plated in quadruplicate and incu-
bated for 1.5 h at 37 C. Cells were washed with PBS, fixed, and stained in
0.5% crystal violet in 20% MeOH/PBS. Cells were washed extensively
with H2O, solubilized with 1% SDS, and absorbance read at 590 nm.
Migration assay
Cell migration assays were performed using modified Boyden chambers
(Transwell-Costar Corp.) coated with 10  g/ml fibronectin. Subconfluent
cells were trypsinized (0.01% trypsin/5 mM EDTA; Cambrex), neutral-
ized (Cascade Biologics, Inc.), washed with EBM/0.1% BSA, and resus-
pended. Cells were pretreated with inhibitors for 30 min in suspension.
Typically, 5   10
5 cells were added to the top of each migration chamber
and were allowed to migrate to the underside of the chamber for 4 h in
the presence or absence of VEGF (3–5 ng/ml) in the lower chamber. Cells
were fixed and stained (Hema 3 Stain System; Fisher Diagnostics). The
number of migrated cells per membrane was captured using bright-field
microscopy connected to a Spot digital camera (Diagnostic Instruments).
Migrated cells from the captured image were counted using NIH Image
software. Each determination represents the average of three individual
wells, and error bars represent the SD. Migration was normalized to per-
cent migration, with migration to VEGF alone representing 100% migra-
tion. Due to the variability inherent in endothelial cell migration assays, a
threefold increase in VEGF-induced migration over basal levels was con-
sidered the minimum criteria for an experiment to be considered valid.
Each experiment was repeated a minimum of three times to ensure data
consistency. Data were analyzed with a two-sided unpaired t test. For all
statistical comparisons, cell treatments were compared with VEGF alone,
except in experiments where antibodies were used, in which case cell
treatments were compared with antibodies alone.
siRNA transfection
 1 and  3 integrin siRNAs were purchased as four oligonucleotide Smart-
Pools (Dharmacon Research, Inc.), containing an approximate 50% guani-
dine-cytosine content (Dharmacon Research, Inc.). The control sequence
used was fluorescein siRNA with an approximate guanidine-cytosine con-
tent of 50% (QIAGEN). The Akt siRNA was commercially available as a
SmartPool (Cell Signaling). HUVEC were trypsinized, washed with HBSS,
and resuspended (10
6 cells) in HUVEC solution (Amaxa Biosystems) con-
taining 1 nM siRNA duplex, and were transfected using a Nucleoporator
(Amaxa Biosystems) following the manufacturer’s instructions. After trans-
fection, cells were immediately plated in dishes containing complete me-
dia. The following day cells were split, and 48 h later either lysed or sub-
jected to migration assays, as described.
Cell treatment, immunoprecipitation, and immunoblotting
For conditions where lysates were examined by Western analysis, subcon-
fluent HUVEC were serum starved for 4 h before treatment with pharmaco-
logical inhibitors, TSR, or growth factors. Pharmacological inhibitors were
added for 15 min. TSR was typically added for 2–4 h. VEGF was added
for 5 min before cell harvest. Lysate preparation and Western analysis
were performed as described previously (Short et al., 1998). For immuno-
precipitations, cell lysates were incubated with primary antibody over-
night at 4 C, followed by incubation with protein G–Sepharose for 1 h at
4 C. Bead complexes were washed with cold radioimmunoprecipitation
assay buffer and boiled with SDS-PAGE sample buffer. Immunoreactivity
was detected on Hyperfilm using ECL (Amersham Biosciences). Images
from ECL autoradiograms were captured using Adobe software.
Bead coating and isolation of supramolecular complexes
Aliquots of Sphero carboxyl Ferro magnetic beads (4.5  m; Spherotech-
nic) were coated as recommended by the manufacturer. In brief, beads
were coated for 2 h in 0.01 M sodium acetate, pH 5.0, containing 1.25
mg/ml EDAC (Sigma-Aldrich) and 0.3 mg ligand/ml beads. Beads were
washed with HBSS/1% HSA and kept in the same solution until added
to cells. HUVEC were incubated for 2 h in HBSS/1% HSA, briefly tryp-
sinized, washed, and held in suspension for 30 min at RT. Cells (0.15  
10
6 per condition) were resuspended in HBSS/0.1% HSA containing 0.1
mM MnCl2. Isolation of supramolecular complexes was performed as de-
scribed previously (Plopper and Ingber, 1993; Green et al., 1999). SDS-
PAGE sample buffer was added, and samples were heated for 10 min at
65 C and analyzed by SDS-PAGE and Western blotting.
For immunoprecipitation experiments, suspension cells were pel-
leted and lysed with 1% digitonin buffer containing 150 mM NaCl, 20
mM Tris-HCl, pH 7.4, 25 mM NaF, 5 mM EDTA, 1 mM Na3VO4, and 1
mM PMSF. 900  g of total cell lysate was incubated overnight at 4 C with
10  l of coated beads. Beads were washed three times with the same
buffer containing 0.2% digitonin. For more stringent conditions, cells were
lysed in 1.5% CHAPS buffer containing 50 mM Tris-HCL, pH 7.5, 150
mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, and 2 mg/ml apro-
tinin. Bead fractions were washed the next day using 1% NP-40 buffer
containing 137 NaCl, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol, 20 mM
Tris-HCl, pH 7.4, 50 mM NaF, 1 mM Na3VO4, and 1 mM PMSF.
Immunofluorescence
HUVEC were plated on fibronectin-coated coverslips (10  g/ml) for 2 h in
serum-free EBM. Magnetic beads coated with integrin-specific antibodies,
HSA, RGD, or TSR were added and allowed to adhere for 30 min. Cells
were gently washed with PBS, fixed in 3.7% formaldehyde in PBS, and per-
meabilized with 0.5% Triton X-100/PBS. Nonspecific staining was blocked
with 2% BSA and coverslips were incubated with primary antibodies
against  5 1 in 2% BSA/PBS. Coverslips were washed extensively with
PBS and stained with TRITC-conjugated goat anti–mouse IgG in 2% BSA/
PBS for 30 min. Coverslips were washed in PBS, rinsed in deionized water,
mounted in Permafluor, and viewed on a microscope (TE-2000 E; Nikon).
Preparation of myristoylated p110 retrovirus
10  g of vector or myristoylated p110 constructs (pLNCX) was transfected
in the Phoenix-Ampho packaging cell line (Dal Canto et al., 1999). Viral
supernatant was collected after 24 or 48 h and passed through a 0.45-
 m filter. Subconfluent cells were incubated with viral supernatant in the
presence of 8  g/ml polybrine in serum containing media and incubated
overnight. Cells were then split and 48 h later used in either the migration
assay or lysed for protein expression analysis.
Flow cytometry
Flow cytometric measurements of integrin subtypes expressed on the sur-
face of endothelial cells was performed as described previously (Short et
al., 1998), using a FACS Vantage SE instrument (Becton Dickinson). Data
were analyzed using CellQuest software (Becton Dickinson), and relative
fluorescence intensity was expressed as a percentage of  1 fluorescence.
Online supplemental material
A supplemental figure (Fig. S1) has been made available at http://
www.jcb.org/cgi/content/full/jcb.200407060/DC1).
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